Atara Biotherapeutics, Inc. (ATRA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-01

Key Insights

Atara has fallen below Nasdaq's $50 million minimum market value requirement and received a delisting notice, indicating severe financial distress and shareholder value deterioration.
The company has 180 calendar days until October 27, 2026 to regain compliance by achieving a $50M+ market value for 10 consecutive business days, but faces uncertainty in achieving this milestone.
Management has acknowledged potential options including transfer to Nasdaq Capital Market, but provided no concrete plan or timeline for resolving the listing violation, suggesting limited near-term remediation strategies.
The filing contains forward-looking statements with substantial risk disclaimers and references to undisclosed risk factors in prior 10-K filings, warning investors of material uncertainties beyond the delisting issue.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-16

Atara Biotherapeutics announced its financial results for Q4 and full-year 2025, indicating the company's operational progress during that period.
The press release accompanying the 8-K filing provides details on the company's financial performance, which investors will want to review carefully.
The 8-K filing itself does not contain any major announcements or material events, but the accompanying financial information is still significant for understanding the company's current state.

Filed: 2026-03-12

Atara Biotherapeutics has scheduled a Type A meeting with the FDA to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application, indicating potential progress in addressing the regulatory concerns.
The company is working closely with its partner, Pierre Fabre Pharmaceuticals, to collaborate with the FDA and resubmit the BLA with additional efficacy data collected since the original submission.
Atara is confident in the potential of its allogeneic Epstein-Barr virus (EBV) T-cell platform and is committed to bringing tabelecleucel (tab-cel) to market for patients with EBV+ PTLD.

Filed: 2026-01-12

Atara Biotherapeutics received a Complete Response Letter from the FDA for its EBVALLO (tabelecleucel) Biologics License Application, indicating further regulatory review is required before approval.
The company's cash, cash equivalents and short-term investments position as of December 31, 2025 was preliminarily disclosed, which provides insight into its current financial condition.
Investors should monitor the company's progress with EBVALLO and the potential impact of the regulatory setback on its business and outlook.

Filed: 2026-01-02

Atara Biotherapeutics has reached a new agreement with Pierre Fabre Medicament to reduce milestone payments related to the approval of tab-cel by the FDA, but gain a potential $15 million commercial milestone payment.
The reduction in milestone payments may provide near-term financial benefits for Atara, but the company is trading off potential upside from tab-cel's approval.
The amended agreement suggests Atara and Pierre Fabre are working to optimize the commercial partnership for tab-cel, though the long-term impact on the company's financials is unclear.

Other reports for Atara Biotherapeutics, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.